Cargando…
Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease
COVID-19 is a disease caused by SARS-CoV-2, which has led to more than 4 million deaths worldwide. As a result, there is a worldwide effort to develop specific drugs for targeting COVID-19. Papain-like protease (PLpro) is an attractive drug target because it has multiple essential functions involved...
Autores principales: | Xu, Yunxia, Chen, Ke, Pan, Juanli, Lei, Yingshou, Zhang, Danting, Fang, Lipei, Tang, Jinle, Chen, Xin, Ma, Yanhong, Zheng, Yi, Zhang, Bao, Zhou, Yaoqi, Zhan, Jian, Xu, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342870/ https://www.ncbi.nlm.nih.gov/pubmed/34364941 http://dx.doi.org/10.1016/j.ijbiomac.2021.07.184 |
Ejemplares similares
-
Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs
por: Kouznetsova, Valentina L., et al.
Publicado: (2020) -
Investigating Derivatives
of Tanshinone IIA Sulfonate
Sodium and Chloroxine for Their Inhibition Activities against the
SARS-CoV-2 Papain-like Protease
por: Chen, Xin, et al.
Publicado: (2022) -
Repurposing of FDA Approved Drugs Against SARS-CoV-2 Papain-Like Protease: Computational, Biochemical, and in vitro Studies
por: Kulandaisamy, Rajkumar, et al.
Publicado: (2022) -
Repurposing Known Drugs as Covalent and Non-covalent Inhibitors of the SARS-CoV-2 Papain-Like Protease
por: Delre, Pietro, et al.
Publicado: (2020) -
Role of Papain-Like Cysteine Proteases in Plant Development
por: Liu, Huijuan, et al.
Publicado: (2018)